Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
10/2000
10/26/2000CA2364209A1 49 human secreted proteins
10/26/2000CA2363689A1 Compounds useful as phosphotyrosine mimics
10/26/2000CA2330231A1 Composition and method for modulating dendritic cell-t cell interaction
10/26/2000CA2330022A1 Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) and surfactant depletion
10/25/2000EP1046651A1 Composition and method for modulating dendritic cell-T interaction
10/25/2000EP1046397A2 Novel bioactivating substance
10/25/2000EP1045920A1 Nucleotide expression systems with reduced immunogenicity for use in gene therapy
10/25/2000EP1045915A2 Regulation of biological events using multimeric chimeric proteins
10/25/2000EP1045908A2 Human urotensin ii
10/25/2000EP1045862A1 Polypeptides, dna coding therefor, formulations thereof, and their use in inhibiting factor xii activation
10/25/2000EP1045861A1 Antibody/receptor targeting moiety for enhanced delivery of armed ligand
10/25/2000EP1045850A1 Purine compounds having pde iv inhibitory activity and methods of synthesis
10/25/2000EP1045849A1 Purine derivatives having phosphodiesterase iv inhibition activity
10/25/2000EP1045845A1 N-oxides of heterocyclic compounds with tnf and pde-iv inhibiting activity
10/25/2000EP1045836A1 Pyridones as src family sh2 domain inhibitors
10/25/2000EP1045822A1 Certain diterpenes and extracts or concentrates of curcuma amada containing them for use as medicaments
10/25/2000EP1045701A1 Methods of using human receptor protein 4-1bb
10/25/2000EP1045700A1 Oral delivery of nucleic acid vaccines by particulate complexes
10/25/2000EP1045699A1 Genetic immunization with co-delivery of nucleic acid and cytokines in a single vehicle
10/25/2000EP1045690A1 Benzenesulfonamide inhibitors of pde-iv and their therapeutic use
10/25/2000CN1271386A Amino-terminally trancated RANTES as chemokine antagonists
10/25/2000CN1271385A Amino-terminally truncated MCP-2 as chemokine antagnosits
10/25/2000CN1271361A Tetrazole-containing rapamycin analogs with shortened half-lives
10/25/2000CN1271353A Furansulfonic acid derivatives and pharmaceutical compositions containing the same
10/25/2000CN1271347A 1,5-diphenylpypazole derivatives
10/25/2000CN1271279A Amide derivatives for the treatment of diseases mediated by cytokines
10/25/2000CN1270838A Adjuvant used in vaccine
10/25/2000CN1270816A Youth and longevity pellet and its preparation
10/25/2000CN1057772C Compounds and compositions for treatment of immunomediated inflammatory disorders
10/24/2000US6136974 Pyrrolo[3,4-D]Pyrimidinone derivatives and their use as medicaments
10/24/2000US6136969 Azepanes
10/24/2000US6136848 Antiallergens; asthma therapy
10/24/2000US6136844 5-aroylpyrrol-2-ylmethylarene derivatives
10/24/2000US6136839 Using a sulfone or sulfoamide benzene compound
10/24/2000US6136817 Opioid receptor antagonist compounds
10/24/2000US6136797 Phospholipid derivatives of phosphono-carboxylic acids, the production of said derivatives and the use of said derivatives as antiviral medicaments
10/24/2000US6136787 Interleukin 1β protease and interleukin 1β protease inhibitors
10/24/2000US6136596 Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
10/24/2000US6136563 With defined substitutions for enhanced affinity for its receptor
10/24/2000US6136357 Anhydrous; cyclosporin; monoglycerides, diglycerides, and/or triglycerides of natural fatty acids; natural fatty acids and/or their alkaline salts; a substance containing 3-sn-phosphatidyl choline and/or phosphatidyl ethanolamine
10/24/2000US6136332 Dermatological/pharmaceutical compositions comprising volatile oils/phenylated silicone oils
10/24/2000US6136323 Forming immunology response
10/24/2000US6136319 Method of treating viral diseases in animals
10/24/2000US6136310 Recombinant anti-CD4 antibodies for human therapy
10/24/2000US6136309 Antibodies against the interferon (IFN) α/β receptor (IFNAR2) that preferentially block the activity of IFN-α
10/24/2000CA2139664C Covalent polar lipid-peptide conjugates for biological targeting
10/19/2000WO2000061792A1 Novel essential bacterial genes and their proteins
10/19/2000WO2000061779A1 49 human secreted proteins
10/19/2000WO2000061774A2 Bone morphogenic proteins
10/19/2000WO2000061762A1 RECOMBINANT TOXIN A/TOXIN B VACCINE AGAINST $i(CLOSTRIDIUM DIFFICILE)
10/19/2000WO2000061757A1 Tumor necrosis factor homologs and nucleic acids encoding the same
10/19/2000WO2000061754A2 Human proteins and polynucleotides encoding them
10/19/2000WO2000061750A2 TYROSINE KINASE SUBSTRATE (Tks) PROTEINS
10/19/2000WO2000061748A1 48 human secreted proteins
10/19/2000WO2000061736A2 Recombinant and mutant marek's disease virus
10/19/2000WO2000061632A1 Interaction of mhc class ii proteins with members of the pcna family of proteins
10/19/2000WO2000061628A1 49 human secreted proteins
10/19/2000WO2000061627A1 49 human secreted proteins
10/19/2000WO2000061625A1 48 human secreted proteins
10/19/2000WO2000061621A2 Flea head, nerve cord, hindgut and malpighian tubule nucleic acid molecules, proteins and uses thereof
10/19/2000WO2000061620A1 49 human secreted proteins
10/19/2000WO2000061608A2 Low-molecular inhibitors of complement proteases
10/19/2000WO2000061604A2 Pharmaceutical compounds
10/19/2000WO2000061602A1 Antisense oligonucleotide modulation of stat3 expression
10/19/2000WO2000061596A1 50 human secreted proteins
10/19/2000WO2000061595A1 The novel antisense-oligos with better stability and antisense effect
10/19/2000WO2000061583A1 Xanthine derivatives and analogs as cell signaling inhibitors
10/19/2000WO2000061582A1 Substituted fused imidazole derivatives
10/19/2000WO2000061581A1 Amine derivatives
10/19/2000WO2000061580A1 Substituted bicyclic heteroaryl compounds as integrin antagonists
10/19/2000WO2000061569A1 Adamantane derivatives
10/19/2000WO2000061552A1 N-SUBSTITUTED-N'-SUBSTITUTED UREA DERIVATIVE AND USE THEREOF AS TNF-α PRODUCTION INHIBITOR
10/19/2000WO2000061542A1 Caspase inhibitors and the use thereof
10/19/2000WO2000061184A2 Dry formulation for transcutaneous immunization
10/19/2000WO2000061181A1 USE OF mCRP TO ENHANCE IMMUNE RESPONSES
10/19/2000WO2000061171A2 Uses of mammalian ox2 protein and related reagents
10/19/2000WO2000061157A1 Methods for skewing the balance between th1 and th2 immune responses
10/19/2000WO2000061150A1 Antisense modulation of fas mediated signaling
10/19/2000WO2000061132A1 Compositions containing immunotoxins and agents that inhibit dendritic cell maturation for inducing immune tolerance to a graft
10/19/2000WO2000061121A2 Use of molecular weight-amplified hirudin as an anticoagulant in extracorporeal renal replacement therapy
10/19/2000WO2000060950A1 Dietary supplement derived from fermented milks for the prevention of osteoporosis
10/19/2000WO2000041505A3 Anthranilic acid derivatives
10/19/2000WO2000035484A3 Methods and compositions for decreasing allergic reactions to surface allergens
10/19/2000WO2000034485A3 Beta-1,3-galactosyltransferase homologs
10/19/2000WO2000034296A3 Conjugates comprising galactose alpha 1,3 galactosyl epitopes and methods of using same
10/19/2000WO2000032223A3 Therapeutic treatment with immunogenic drugs
10/19/2000WO2000013702A9 Use of an angiogenic factor for the treatment of microvascular angiopathies
10/19/2000DE19917930A1 Treating estrogen deficiency associated disorders, e.g. menopausal problems, osteoporosis, neoplasia or neurodegenerative disease, using new or known ent-steroids having bone-selective estrogenic activity
10/19/2000DE19917505A1 Treating cytokine-mediated diseases, e.g. asthma, allergy, eczema, rheumatoid arthritis or transplant rejection, using new or known maduraphthalazine derivatives
10/19/2000DE19917195A1 New peptide derived from the MUC-1 tumor marker, used to induce a cytotoxic T cell response for treatment or prevention of tumors
10/19/2000DE19917098A1 New immunogenic polypeptides from methicillin-resistant Staphylococcus aureus, useful for raising human antibodies for treating infections
10/19/2000DE19915465A1 Verwendung eines Caspase-Inhibitors zur Proliferationshemmung von Zellen und Verwendung eines oder mehrerer Caspase-Inhibitors/en zur Behandlung von Erkrankungen beruhend auf Lymphozyten-Hyperproliferation oder zur Suppression einer Immunantwort durch Lymphozyten Using a Caspase inhibitor for the inhibition of proliferation of cells and using one or more caspase inhibitor / s for the treatment of diseases based on lymphocyte hyperproliferation or for suppression of an immune response by lymphocytes
10/19/2000DE19915057A1 Monoklonale Antikörper gegen das humane Mcm3 Protein, Verfahren zu ihrer Herstellung und ihre Verwendung Monoclonal antibodies to human protein Mcm3, processes for their preparation and their use
10/19/2000CA2815763A1 Anti-bacterial vaccine compositions
10/19/2000CA2382628A1 Compositions containing immunotoxins and agents that inhibit dendritic cell maturation for inducing immune tolerance to a graft
10/19/2000CA2372028A1 Flea head, nerve cord, hindgut and malpighian tubule nucleic acid molecules, proteins and uses thereof
10/19/2000CA2371223A1 49 human secreted proteins
10/19/2000CA2371172A1 50 human secreted proteins
10/19/2000CA2370767A1 49 human secreted proteins
10/19/2000CA2370523A1 49 human secreted proteins
1 ... 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 ... 1172